|
Liver carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
<i>TERT-CLPTM1</i> locus polymorphism (rs401681) is associated with the prognosis of hepatocellular carcinoma.
|
29042796 |
2017 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Telomerase reverse transcriptase mRNA expression and telomerase activity in hepatocellular carcinoma.
|
10204615 |
1999 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Telomerase reverse transcriptase (TERT), which encodes the catalytic subunit of telomerase, is highly expressed in a variety of invasive cancers, including HCC.
|
24732358 |
2014 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
TERT protein levels were higher in HCC (n = 28) compared to normal liver tissues (n = 8) (p =0.001), but did not differ between mutated and non-mutated tumor tissues.
|
27056898 |
2016 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
TERT promotermutations were significantly more frequent in hepatocellular carcinomas related to hepatitis C virus infection (5/6; 83.3%) compared to tumors of other etiologies (P = 0.001).
|
27661004 |
2016 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
TERT overexpression was the only significant prognostic factor for late IHR in HCC treated with curative resection.
|
28947783 |
2017 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Alpha-fetoprotein and human telomerase reverse transcriptase mRNA levels in peripheral blood of patients with hepatocellular carcinoma.
|
19184104 |
2009 |
|
Liver carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Although main HCC oncogenic drivers have been deciphered in recent years (TERT, TP53, CTNNB1 mutations, miR122 and CDKN2A silencing), therapeutic applications derived from this molecular knowledge are still limited.
|
31783782 |
2019 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
As hypermethylation was positively correlated with high expression of TERT in HCC, TERT is likely to be involved in the aetiology of HCC.
|
25683523 |
2015 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Because the TERT activity is elevated in most cases of hepatocellular carcinoma (HCC), the current study aims to investigate whether Telomelysin can be used for treatment of HCC.
|
22886913 |
2013 |
|
Liver carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
|
25574106 |
2015 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Consistently, TERT expression levels in RNs were comparable to those in normal livers, whereas every HCC tissue demonstrated an elevated level of TERT expression.
|
30756187 |
2019 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
CpG island methylator phenotype association with upregulated telomerase activity in hepatocellular carcinoma.
|
18546260 |
2008 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma.
|
16729333 |
2006 |
|
Liver carcinoma
|
0.600 |
PosttranslationalModification
|
disease |
BEFREE |
Depletion of sirtuin 1 (SIRT1) leads to epigenetic modifications of telomerase (TERT) gene in hepatocellular carcinoma cells.
|
24416313 |
2014 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Development of a novel assay to quantify serum human telomerase reverse transcriptase messenger RNA and its significance as a tumor marker for hepatocellular carcinoma.
|
18087181 |
2007 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
Dynamic alteration of telomerase expression and its diagnostic significance in liver or peripheral blood for hepatocellular carcinoma.
|
16937491 |
2006 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.
|
25822088 |
2015 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
LHGDN |
Expression of telomerase activity and oxidative stress in human hepatocellular carcinoma with cirrhosis.
|
12918139 |
2003 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Finally, TERT localizes in mitochondria in HCC, where it lacks a canonical function.
|
26408804 |
2016 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, knockdown of human telomerase reverse transcriptase expression mitigated the hepatitis B virus core protein-enhanced hepatocellular carcinoma cell proliferation and clone formation in vitro.
|
23542016 |
2013 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Genetic diagnostic test of hepatocellular carcinoma by telomerase catalytic subunit mRNA.
|
9769378 |
1998 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
h-TERT mRNA seemed to prove more valuable than AFP mRNA not only to assess preoperative treatment modalities and postoperative patient surveillance, but also to evaluate prospective LDLT patients with HCC.
|
17175353 |
2006 |
|
Liver carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Here we analyzed the TERT promoter status and genotyped the TERT SNPs at rs2736098 and rs2736100 in patients with HCC.
|
28416747 |
2017 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Here, in a hepatocellular carcinoma-prone model brought about through toxin-induced hepatocyte injury and regeneration, we sought to determine the cooperative interactions of germ line p53 mutation and telomere dysfunction [produced by telomerase reverse transcriptase (mTERT) gene knockout].
|
16651430 |
2006 |